JMP Securities Reiterates Market Outperform on Inhibrx, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on Inhibrx (NASDAQ:INBX) and maintained a price target of $27.
November 20, 2023 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin reaffirmed a 'Market Outperform' rating on Inhibrx, with a price target of $27, indicating a positive outlook for the stock.
The reiteration of a 'Market Outperform' rating and the maintenance of a $27 price target by a reputable analyst could lead to increased investor confidence in INBX, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100